FFRct vs Tempus ECG-AF
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
FFRct is a diagnostic tool for coronary artery disease, utilizing CCTA scans to assess blood flow and guide treatment strategies. In contrast, Tempus ECG-AF is a risk stratification tool that analyzes 12-lead ECGs to identify older patients at increased risk of developing new-onset atrial fibrillation. While both are cardiology AI solutions, they address distinct cardiac conditions and leverage different input data for their respective clinical applications.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
HeartFlow FFRct Analysis is a non-invasive AI-powered diagnostic tool that creates personalized 3D models of coronary arteries from CCTA scans to assess blood flow and aid in diagnosing coronary artery disease (CAD). Tempus ECG-AF is an FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up.
FFRct is designed for patients with chest pain or other symptoms suggestive of CAD, particularly those who have undergone a CCTA scan and have detected blockages. Tempus ECG-AF is specifically for patients aged 65 or older without a known history of AF, pacemakers, implantable cardioverter defibrillators (ICDs), or recent cardiac surgery.
HeartFlow FFRct Analysis utilizes data from CCTA scans to generate personalized 3D digital models of coronary arteries. Tempus ECG-AF analyzes standard 12-lead ECG recordings.
The CMS payment rate for FFRct Analysis is $1,017 (2025), with commercial payer rates varying, and it uses CPT code 75580. Tempus ECG-AF has CMS reimbursement available under CPT 0764T and CPT 0765T, assigned to APC 5734, with a Medicare rate of $128.90, effective January 1, 2025.
FFRct generates personalized 3D models of coronary arteries and analyzes blood flow to provide FFRct values, helping physicians assess the physiological impact of blockages and guide treatment strategies for CAD. Tempus ECG-AF provides a result indicating an 'increased risk' or 'no increased risk' of new onset AF within 12 months, which should be interpreted with other diagnostic information and clinical history to consider the need for follow-up.